JPH09502161A - 補足された及び補足されていない組織シーラント、その製造法及び使用法 - Google Patents
補足された及び補足されていない組織シーラント、その製造法及び使用法Info
- Publication number
- JPH09502161A JPH09502161A JP6520353A JP52035394A JPH09502161A JP H09502161 A JPH09502161 A JP H09502161A JP 6520353 A JP6520353 A JP 6520353A JP 52035394 A JP52035394 A JP 52035394A JP H09502161 A JPH09502161 A JP H09502161A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- drug
- tissue sealant
- supplemented
- fibrin glue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1825—Fibroblast growth factor [FGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/363—Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/32—Proteins, polypeptides; Degradation products or derivatives thereof, e.g. albumin, collagen, fibrin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L24/00—Surgical adhesives or cements; Adhesives for colostomy devices
- A61L24/001—Use of materials characterised by their function or physical properties
- A61L24/0015—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0028—Polypeptides; Proteins; Degradation products thereof
- A61L26/0042—Fibrin; Fibrinogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0085—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/402—Anaestetics, analgesics, e.g. lidocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Materials Engineering (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Oncology (AREA)
- Heart & Thoracic Surgery (AREA)
- Inorganic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.組織シーラントおよび薬物とからなることを特徴とする組成物。 2.充実肥厚皮膚の傷治療を抑制しない請求項1の組成物。 3.該組織シーラントがフィブリン膠である請求項1または2の組成物。 4.組織シーラントおよび薬物とからなることを特徴とする薬物の局所放出を促 進する組成物。 5.該薬物が固体である請求項5の組成物。 6.該固体が該薬物の水難溶性形である請求項5の組成物。 7.該薬物が抗生物質である請求項4、5または6の組成物。 8.該薬物がテトラサイクリン遊離塩基である請求項4、5、6または7の組成 物。 9.該抗生物質がテトラサイクリン塩酸塩である請求項7の組成物。 10.該抗生物質がシプロフロキサシン塩酸塩である請求項7の組成物。 11.該薬物が抗増殖剤である請求項4の組成物。 12.該薬物が5−フルオロウラシルである請求項4、5または11の組成物。 13.該組織シーラントがフィブリン膠である請求項4、5、6または11の組 成物。 14.該組織シーラントがフィブリン膠である請求項7の組成物。 15.該組織シーラントがフィブリン膠である請求項8の組成物。 16.該組織シーラントがフィブリン膠である請求項9の組成物。 17.該組織シーラントがフィブリン膠である請求項10の組成物。 18.該組織シーラントがフィブリン膠である請求項12の組成物。 19.組織シーラントおよび薬物からなる組成物を組織に適用することを特徴と する薬物を組織へ局所放出する方法。 20.該組成物が請求項4、5、6または11のいずれかの組成物である請求項 19の方法。 21.該組成物が請求項7の組成物である請求項19の方法。 22.該組成物が請求項8の組成物である請求項19の方法。 23.該組成物が請求項9の組成物である請求項19の方法。 24.該組成物が請求項10の組成物である請求項19の方法。 25.該組成物が請求項12の組成物である請求項19の方法。 26.該組成物が請求項13の組成物である請求項19の方法。 27.該組成物が請求項14の組成物である請求項19の方法。 28.該組成物が請求項15の組成物である請求項19の方法。 29.該組成物が請求項16の組成物である請求項19の方法。 30.該組成物が請求項17の組成物である請求項19の方法。 31.該組成物が請求項18の組成物である請求項19の方法。 32.組織シーラントおよびその寿命をさらに延長するのに有効な量の補薬を含 む、延長された寿命を有する補薬添加組織シーラントからなる組成物。 33.該寿命がインビトロで延長される請求項32の組成物。 34.該補薬が固体である請求項32の組成物。 35.該固体が該薬物の水難溶性形である請求項34の組成物。 36.該補薬がテトラサイクリン遊離塩基である請求項32、33、34または 35の組成物。 37.該補薬がシプロフロキサシン塩酸塩である請求項32、33、34または 35の組成物。 38.該組織シーラントがフィブリン膠である請求項32、33、34または3 5の組成物。 39.該組織シーラントがフィブリン膠である請求項36の組成物。 40.該組織シーラントがフィブリン膠である請求項37の組成物。 41.組織シーラントを含む自給式組織シーラント傷用医療材料。 42.成長因子をさらに含む請求項41の傷用医療材料。 43.該成長因子が線維芽細胞成長因子である請求項41の傷用医療材料。 44.薬物をさらに含む請求項41の傷用医療材料。 45.該薬物が抗生物質である請求項44の傷用医療材料。 46.該薬物が鎮痛剤である請求項44の傷用医療材料。 47.該組織シーラントがフィブリン膠である請求項41、42、43、44、 45または46の傷用医療材料。 48.薬物を補充した組織シーラントの製造法。 49.該組織シーラント(TS)が固定する前に該TSと薬物を混合する請求項 48の方法。 50.該薬物が固体である請求項48または49の方法。 51.該固体が該薬物の水難溶性形である請求項50の方法。 52.該薬物がテトラサイクリン遊離塩基である請求項48、49、50または 51の方法。 53.該薬物がシプロフロキサシン塩酸塩である請求項48、49、50または 51の方法。 54.該薬物が5−フルオロウラシルである請求項48、49、50または51 の方法。 55.該組織シーラントがフィブリン膠である請求項48または49の方法。 56.該組織シーラントがフィブリン膠である請求項50の方法。 57.該組織シーラントがフィブリン膠である請求項51の方法。 58.該組織シーラントがフィブリン膠である請求項52の方法。 59.該組織シーラントがフィブリン膠である請求項53の方法。 60.該組織シーラントがフィブリン膠である請求項54の方法。 61.その混合物を固定する前に該薬物をフィブリノーゲン濃厚物、トロンビン および塩化カルシウムと混合する請求項55の方法。 62.該組織シーラントを該薬物を含有する溶液に浸漬する請求項48の方法。 63.組織シーラントおよび薬物からなる組成物を生体物質に適用することを特 徴とする生体物質の表面を被覆する方法。 64.該薬物が抗生物質である請求項63の方法。 65.該組成物がさらに細胞を含む請求項63の方法。 66.該細胞が内皮細胞、骨芽細胞または線維芽細胞である請求項65の方法。 67.該生体物質が整形外科用具または人工血管である請求項63の方法。 68.該組織シーラントがフィブリン膠である請求項63、64、65、66ま たは67の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US3116493A | 1993-03-12 | 1993-03-12 | |
US08/031,164 | 1993-03-12 | ||
PCT/US1994/002708 WO1994020133A1 (en) | 1993-03-12 | 1994-03-14 | Supplemented and unsupplemented tissue sealants, methods of their production and use |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006178637A Division JP2006297130A (ja) | 1993-03-12 | 2006-06-28 | 補足された及び補足されていない組織シーラント、その製造法及び使用法 |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09502161A true JPH09502161A (ja) | 1997-03-04 |
Family
ID=21857957
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP6520353A Withdrawn JPH09502161A (ja) | 1993-03-12 | 1994-03-14 | 補足された及び補足されていない組織シーラント、その製造法及び使用法 |
JP2006178637A Pending JP2006297130A (ja) | 1993-03-12 | 2006-06-28 | 補足された及び補足されていない組織シーラント、その製造法及び使用法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006178637A Pending JP2006297130A (ja) | 1993-03-12 | 2006-06-28 | 補足された及び補足されていない組織シーラント、その製造法及び使用法 |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP0696201B2 (ja) |
JP (2) | JPH09502161A (ja) |
AT (1) | ATE271882T1 (ja) |
AU (1) | AU696691C (ja) |
CA (1) | CA2158134C (ja) |
DE (1) | DE69433920T2 (ja) |
ES (1) | ES2225828T3 (ja) |
WO (1) | WO1994020133A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003500172A (ja) * | 1999-06-01 | 2003-01-07 | ブリストル−マイヤーズ スクイブ カンパニー | フィブリンポリマー構造体 |
JP2009131649A (ja) * | 1997-03-20 | 2009-06-18 | Stryker Corp | 骨の修復のための骨形成デバイスおよびその使用 |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6117425A (en) * | 1990-11-27 | 2000-09-12 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, method of their production and use |
US6054122A (en) * | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6559119B1 (en) | 1990-11-27 | 2003-05-06 | Loyola University Of Chicago | Method of preparing a tissue sealant-treated biomedical material |
US7196054B1 (en) | 1990-11-27 | 2007-03-27 | The American National Red Cross | Methods for treating wound tissue and forming a supplemented fibrin matrix |
US6197325B1 (en) | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
US6919067B2 (en) | 1991-09-13 | 2005-07-19 | Syngenix Limited | Compositions comprising a tissue glue and therapeutic agents |
WO1996003112A1 (en) * | 1993-05-04 | 1996-02-08 | Syngenix Limited | Compositions comprising a tissue glue and therapeutic agents |
CN1091315A (zh) * | 1992-10-08 | 1994-08-31 | E·R·斯奎布父子公司 | 血纤维蛋白封闭剂组合物及其使用方法 |
EP0785774B1 (en) * | 1994-10-12 | 2001-01-31 | Focal, Inc. | Targeted delivery via biodegradable polymers |
JP4223548B2 (ja) * | 1994-12-07 | 2009-02-12 | ジ・アメリカン・ナショナル・レッド・クロス | 補足または非補足組織シーラント、それらの製法および使用 |
EP0869804A4 (en) * | 1995-06-07 | 2001-08-16 | American Nat Red Cross | SUPPLEMENTED AND NON-SUPPLEMENTED SEALANTS, METHOD FOR THE PRODUCTION AND USE THEREOF |
US20010016646A1 (en) | 1998-03-20 | 2001-08-23 | David C. Rueger | Osteogenic devices and methods of use thereof for repair of endochondral bone, osteochondral and chondral defects |
AU7977298A (en) * | 1997-06-18 | 1999-01-04 | Cohesion Technologies, Inc. | Compositions containing thrombin and microfibrillar collagen, and methods for preparation and use thereof |
US7241730B2 (en) | 1998-08-27 | 2007-07-10 | Universitat Zurich | Enzyme-mediated modification of fibrin for tissue engineering: fibrin formulations with peptides |
US7601685B2 (en) | 1998-08-27 | 2009-10-13 | Eidgenossische Technische Hochschule Zurich | Growth factor modified protein matrices for tissue engineering |
DE19841698A1 (de) * | 1998-09-11 | 2000-03-16 | Curative Technologies Gmbh | Wachstumsfaktor-enthaltende Zusammensetzung zur Heilung von Gewebeschäden |
US6372494B1 (en) | 1999-05-14 | 2002-04-16 | Advanced Tissue Sciences, Inc. | Methods of making conditioned cell culture medium compositions |
DE60141567D1 (de) | 2000-01-25 | 2010-04-29 | Edwards Lifesciences Corp | Freisetzungssysteme zur behandlung von restenose und anastomotischer intimaler hyperplasie |
US6921532B1 (en) | 2000-06-22 | 2005-07-26 | Spinal Restoration, Inc. | Biological Bioadhesive composition and methods of preparation and use |
NZ523425A (en) * | 2000-06-22 | 2006-02-24 | Spinal Restoration Inc | Biological tissue adhesives comprising fibrin sealant consisiting of fibrinogen and thrombin and a therapeutic agent for use in at discrete site within the body |
GB2369572A (en) | 2000-11-29 | 2002-06-05 | Raft Trustees Ltd | Wound treatment composition comprising insulin |
US6982170B1 (en) | 2001-12-17 | 2006-01-03 | Maine Medical Center Research Institute | Compositions, methods and kits relating to thrombin degradation resistant fibroblast growth factor-1 |
US7247609B2 (en) | 2001-12-18 | 2007-07-24 | Universitat Zurich | Growth factor modified protein matrices for tissue engineering |
US7846141B2 (en) | 2002-09-03 | 2010-12-07 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
GB0224986D0 (en) | 2002-10-28 | 2002-12-04 | Smith & Nephew | Apparatus |
US10058642B2 (en) | 2004-04-05 | 2018-08-28 | Bluesky Medical Group Incorporated | Reduced pressure treatment system |
US7909805B2 (en) | 2004-04-05 | 2011-03-22 | Bluesky Medical Group Incorporated | Flexible reduced pressure treatment appliance |
US8062272B2 (en) | 2004-05-21 | 2011-11-22 | Bluesky Medical Group Incorporated | Flexible reduced pressure treatment appliance |
GB0409446D0 (en) | 2004-04-28 | 2004-06-02 | Smith & Nephew | Apparatus |
US8403923B2 (en) | 2004-10-29 | 2013-03-26 | Spinal Restoration, Inc. | Injection of fibrin sealant in the absence of corticosteroids in spinal applications |
US8419722B2 (en) | 2004-10-29 | 2013-04-16 | Spinal Restoration, Inc. | Apparatus and method for injection of fibrin sealant in spinal applications |
US8124075B2 (en) | 2004-07-16 | 2012-02-28 | Spinal Restoration, Inc. | Enhanced biological autologous tissue adhesive composition and methods of preparation and use |
US7597687B2 (en) | 2004-10-29 | 2009-10-06 | Spinal Restoration, Inc. | Injection of fibrin sealant including an anesthetic in spinal applications |
US8206448B2 (en) | 2004-10-29 | 2012-06-26 | Spinal Restoration, Inc. | Injection of fibrin sealant using reconstituted components in spinal applications |
US8575101B2 (en) | 2005-01-06 | 2013-11-05 | Kuros Biosurgery Ag | Supplemented matrices for the repair of bone fractures |
WO2006073711A2 (en) | 2005-01-06 | 2006-07-13 | Kuros Biosurgery Ag | Use of a matrix comprising a contrast agent in soft tissues |
US7429241B2 (en) | 2005-09-29 | 2008-09-30 | Codman & Shurtleff, Inc. | Dural graft and method of preparing the same |
CN101711168B (zh) | 2007-04-13 | 2013-05-01 | 库罗斯生物外科股份公司 | 聚合物组织封闭剂 |
WO2009020612A1 (en) | 2007-08-06 | 2009-02-12 | Stb Lifesaving Technologies, Inc. | Methods and dressing for sealing internal injuries |
US20120195953A1 (en) * | 2007-09-19 | 2012-08-02 | Kieu Hoang | Fibrin sealant (FIBRINGLURAAS) consisting of a kit of lyophilized high concentrate fribinogen intentionally enriched and preserved with fibronolysis inhibitor A1AT |
US8808259B2 (en) | 2007-11-21 | 2014-08-19 | T.J. Smith & Nephew Limited | Suction device and dressing |
MX2010005552A (es) | 2007-11-21 | 2010-06-02 | Smith & Nephew | Aposito para heridas. |
GB0722820D0 (en) | 2007-11-21 | 2008-01-02 | Smith & Nephew | Vacuum assisted wound dressing |
US11253399B2 (en) | 2007-12-06 | 2022-02-22 | Smith & Nephew Plc | Wound filling apparatuses and methods |
GB0723875D0 (en) | 2007-12-06 | 2008-01-16 | Smith & Nephew | Wound management |
WO2009083544A2 (en) | 2007-12-28 | 2009-07-09 | Kuros Biosurgery Ag | Pdgf fusion proteins incorporated into fibrin foams |
GB0803564D0 (en) | 2008-02-27 | 2008-04-02 | Smith & Nephew | Fluid collection |
US9061095B2 (en) | 2010-04-27 | 2015-06-23 | Smith & Nephew Plc | Wound dressing and method of use |
GB201011173D0 (en) | 2010-07-02 | 2010-08-18 | Smith & Nephew | Provision of wound filler |
MX337627B (es) | 2010-11-25 | 2016-03-10 | Smith & Nephew | Composiciones i-ii y productos y usos de la misma. |
GB201020005D0 (en) | 2010-11-25 | 2011-01-12 | Smith & Nephew | Composition 1-1 |
WO2012123028A1 (en) | 2011-03-16 | 2012-09-20 | Kuros Biosurgery Ag | Pharmaceutical formulation for use in spinal fusion |
US20150159066A1 (en) | 2011-11-25 | 2015-06-11 | Smith & Nephew Plc | Composition, apparatus, kit and method and uses thereof |
US20160120706A1 (en) | 2013-03-15 | 2016-05-05 | Smith & Nephew Plc | Wound dressing sealant and use thereof |
WO2014209620A1 (en) | 2013-06-28 | 2014-12-31 | 3M Innovative Properties Company | Fibrin-coated wound dressing |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61178927A (ja) * | 1981-06-25 | 1986-08-11 | セラフアルム ジ−エムビ−エイチ アンド カンパニ− ケイジイ | フイブリノゲンを含有する乾燥製剤およびその製法 |
US4442655A (en) † | 1981-06-25 | 1984-04-17 | Serapharm Michael Stroetmann | Fibrinogen-containing dry preparation, manufacture and use thereof |
AT369990B (de) * | 1981-07-28 | 1983-02-25 | Immuno Ag | Verfahren zur herstellung eines gewebeklebstoffes |
US4619913A (en) * | 1984-05-29 | 1986-10-28 | Matrix Pharmaceuticals, Inc. | Treatments employing drug-containing matrices for introduction into cellular lesion areas |
ZA875803B (en) * | 1986-08-07 | 1988-03-30 | Hoechst Ag | An antibacterial adhesive film,and a process for its production |
US5171318A (en) * | 1987-11-09 | 1992-12-15 | Chiron Ophthalmics, Inc. | Treated corneal prosthetic device |
US5290552A (en) * | 1988-05-02 | 1994-03-01 | Matrix Pharmaceutical, Inc./Project Hear | Surgical adhesive material |
US5124155A (en) * | 1988-06-21 | 1992-06-23 | Chiron Ophthalmics, Inc. | Fibronectin wound-healing dressings |
US5226877A (en) * | 1989-06-23 | 1993-07-13 | Epstein Gordon H | Method and apparatus for preparing fibrinogen adhesive from whole blood |
US6197325B1 (en) † | 1990-11-27 | 2001-03-06 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
CA2097063C (en) * | 1990-11-27 | 2006-08-08 | Howard P. Greisler | Tissue sealant and growth factor containing compositions that promote accelerated wound healing |
US5206023A (en) * | 1991-01-31 | 1993-04-27 | Robert F. Shaw | Method and compositions for the treatment and repair of defects or lesions in cartilage |
AU1432292A (en) * | 1991-02-07 | 1992-09-07 | Lawrence Samuel Bass | Drug delivery composition and method of using the same |
-
1994
- 1994-03-14 EP EP94910927A patent/EP0696201B2/en not_active Expired - Lifetime
- 1994-03-14 WO PCT/US1994/002708 patent/WO1994020133A1/en active IP Right Grant
- 1994-03-14 AT AT94910927T patent/ATE271882T1/de not_active IP Right Cessation
- 1994-03-14 JP JP6520353A patent/JPH09502161A/ja not_active Withdrawn
- 1994-03-14 DE DE69433920T patent/DE69433920T2/de not_active Expired - Lifetime
- 1994-03-14 AU AU63648/94A patent/AU696691C/en not_active Ceased
- 1994-03-14 ES ES94910927T patent/ES2225828T3/es not_active Expired - Lifetime
- 1994-03-14 CA CA2158134A patent/CA2158134C/en not_active Expired - Fee Related
-
2006
- 2006-06-28 JP JP2006178637A patent/JP2006297130A/ja active Pending
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009131649A (ja) * | 1997-03-20 | 2009-06-18 | Stryker Corp | 骨の修復のための骨形成デバイスおよびその使用 |
JP2012161635A (ja) * | 1997-03-20 | 2012-08-30 | Stryker Corp | 骨の修復のための骨形成デバイスおよびその使用 |
JP2003500172A (ja) * | 1999-06-01 | 2003-01-07 | ブリストル−マイヤーズ スクイブ カンパニー | フィブリンポリマー構造体 |
Also Published As
Publication number | Publication date |
---|---|
AU696691C (en) | 2003-09-18 |
CA2158134A1 (en) | 1994-09-15 |
DE69433920T2 (de) | 2005-06-02 |
EP0696201B2 (en) | 2012-09-19 |
AU696691B2 (en) | 1998-09-17 |
ATE271882T1 (de) | 2004-08-15 |
ES2225828T3 (es) | 2005-03-16 |
EP0696201B1 (en) | 2004-07-28 |
JP2006297130A (ja) | 2006-11-02 |
WO1994020133A1 (en) | 1994-09-15 |
DE69433920D1 (de) | 2004-09-02 |
CA2158134C (en) | 2010-05-04 |
EP0696201A1 (en) | 1996-02-14 |
EP0696201A4 (en) | 1996-06-26 |
AU6364894A (en) | 1994-09-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09502161A (ja) | 補足された及び補足されていない組織シーラント、その製造法及び使用法 | |
JP4223548B2 (ja) | 補足または非補足組織シーラント、それらの製法および使用 | |
US7189410B1 (en) | Supplemented and unsupplemented tissue sealants, methods of their production and use | |
USRE39298E1 (en) | Supplemented and unsupplemented tissue sealants, methods of their production and use | |
USRE39192E1 (en) | Supplemented and unsupplemented tissue sealants, methods of their production and use | |
USRE39321E1 (en) | Supplemented and unsupplemented tissue sealants, methods of their production and use | |
US6559119B1 (en) | Method of preparing a tissue sealant-treated biomedical material | |
JPH11507277A (ja) | 補足された及び補足されていない組織シーラント、その製造法及び使用法 | |
WO1996017633A9 (en) | Supplemented and unsupplemented tissue sealants, methods of their production and use | |
CA2097063C (en) | Tissue sealant and growth factor containing compositions that promote accelerated wound healing | |
JPH11507697A (ja) | キチンヒドロゲル、それらの製造方法及び利用 | |
Bhatnagar et al. | Delivery systems for platelet derived growth factors in wound healing: A review of recent developments and global patent landscape | |
Natesan et al. | PEGylated platelet-free blood plasma-based hydrogels for full-thickness wound regeneration | |
Rožman et al. | The role of platelet gel in regenerative medicine | |
AU733471B2 (en) | Supplemented and unsupplemented tissue sealants, methods of their production and use | |
AU778583B2 (en) | Supplemented and unsupplemented tissue sealants, methods of their production and use | |
RU2462255C1 (ru) | Органоспецифический регенерант gi | |
AU5053200A (en) | Supplemented and unsupplemented tissue sealants, methods of their production and use | |
MX2012007961A (es) | Biomatrices para atraer y retener celulas regenerativas y de reparacion. | |
Caterina | Platelet concentrate and tissue regeneration: does it work? A pre-clinical study |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20041026 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050125 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20050328 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20050426 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050628 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20050928 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20051114 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051228 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060228 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060616 |
|
A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20061204 |